New Additions To Range Of Novel Building Blocks

Endeavour Speciality Chemicals (Endeavour) announced the launch of new additions to its range of novel building blocks and reactive intermediates, including new compounds targeted at Oncology research, a focused selection for researchers studying Nanomaterials and an expansion of its offering of novel Thioamides.

Thioamides in particular are of great interest to researchers working in the pharmaceutical industry, as they are a well-established route to forming Thiazoles - a group of compounds with applications for research into many debilitating diseases. These include auto-immune disorders, cardiovascular disease and cancer. One of the major factors behind this interest is the recent discovery that it is likely to be the presence of the Thiazole ring itself which inhibits tumour growth in certain types of cancer and this revelation will further heighten the significance of this particular branch of chemistry.

With the introduction of the new products, Endeavour will have added over 100 original compounds to its catalogue of over 950 products since the 2010 Informex USA event in San Francisco. Designed for the synthesis of complex molecules, the majority of Endeavours’ products are based on its core technologies of sulphur and heterocyclic chemistry and are often unavailable from other manufacturers. The new, non-exclusive products will be available from stock in small packs (1g - 100g) for early stage R&D or larger quantities (100g - 100kg) for projects moving through the development stage.

Endeavour’s products have applications across industry sectors, including pharmaceuticals, agrochemicals and materials sciences. Together with parent company, Robinson Brothers, Endeavour can support projects from initial development through to full-scale commercial production.